Systimmune reported that izalontamab brengitecan (iza‑bren) met both progression‑free survival and overall survival endpoints in a Phase III trial of Chinese patients with advanced triple‑negative breast cancer. The readout represents a major clinical success for the licensee Bristol Myers Squibb and validates the next‑generation ADC approach in a difficult‑to‑treat population. Company statements indicated statistically significant improvements that supported the primary and key secondary endpoints; full data will inform potential regulatory filings and global development strategies. The result may accelerate partnership and regulatory discussions given the dearth of effective options in advanced TNBC. Sponsors and licensees will now weigh global extrapolation, regulatory alignment, and potential accelerated pathways based on the China trial success.